These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6498057)

  • 41. [Medical treatment of acute disorders of cerebral circulation].
    Buscaino GA
    Acta Neurol Quad (Napoli); 1980; 41():74-81. PubMed ID: 7293741
    [No Abstract]   [Full Text] [Related]  

  • 42. Cerebral vasodilators.
    Judge TG
    Br Med J; 1971 Aug; 3(5772):480. PubMed ID: 4936031
    [No Abstract]   [Full Text] [Related]  

  • 43. The effect of cyclandelate on mental function in patients with arteriosclerotic brain disease.
    Fine EW; Lewis D; Villa-Landa I; Blakemore CB
    Br J Psychiatry; 1970 Aug; 117(537):157-61. PubMed ID: 4921174
    [No Abstract]   [Full Text] [Related]  

  • 44. Electroencephalographic study of dose-response relations for cyclandelate on hyperventilation-induced vasospasm in human brain.
    Korenyi C; Whittier JR
    Angiology; 1969 Oct; 20(9):529-34. PubMed ID: 5824354
    [No Abstract]   [Full Text] [Related]  

  • 45. Cyclandelate in long standing cerebral arteriosclerosis.
    Rogers WF; Shaikh VA; Clark AN
    Gerontol Clin (Basel); 1970; 12(2):88-93. PubMed ID: 4987660
    [No Abstract]   [Full Text] [Related]  

  • 46. [The clinical use of the nicotinic ester of diethylaminoethanol (Euclidan) in cerebral vascular diseases].
    Alloro L; Terenziani S
    Minerva Med; 1968 May; 59(42):2466-73. PubMed ID: 5653338
    [No Abstract]   [Full Text] [Related]  

  • 47. [Clinical evaluation of (-) eburnamonine in chronic cerebrovascular insufficiency].
    De Pergola E; Di Lorenzo L; De Pergola G
    G Clin Med; 1980 Aug; 61(8):628-42. PubMed ID: 7004986
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatment of the cerebral manifestations of arteriosclerosis with cyclandelate.
    Young J; Hall P; Blakemore C
    Br J Psychiatry; 1974 Feb; 124(579):177-80. PubMed ID: 4596673
    [No Abstract]   [Full Text] [Related]  

  • 49. Inhibition of human platelet aggregation by cyclandelate.
    Van den Hoven WE; Hall DW
    Br J Clin Pract Suppl; 1984; 34():34-8. PubMed ID: 6430321
    [No Abstract]   [Full Text] [Related]  

  • 50. [Stability of cyclandelate in a soft capsule].
    Richard J; Andermann G
    Pharm Acta Helv; 1982; 57(4):116-21. PubMed ID: 7089017
    [No Abstract]   [Full Text] [Related]  

  • 51. [Clinical and Neuropsychological changes associated with vincamin treatment in cerebrovascular disease (author's transl)].
    Ambrozi L; Bruck J; Tschabitscher H
    Nervenarzt; 1982 Mar; 53(3):141-3. PubMed ID: 7078689
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical efficacy and central mechanisms of cyclandelate in migraine: a double-blind placebo-controlled study.
    Siniatchkin M; Gerber WD; Vein A
    Funct Neurol; 1998; 13(1):47-56. PubMed ID: 9584874
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pilot study to evaluate the effect of acute and long-term administration of cyclandelate on the vigilance of subjects submitted to hypoxic conditions. Preliminary report.
    Schaffler K; Hörmann E; Arnold H
    Arzneimittelforschung; 1981; 31(6):1032-5. PubMed ID: 7196236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-performance liquid chromatographic method for the determination of a cyclandelate metabolite, mandelic acid, in human plasma.
    Kojima K; Uezono Y; Takahashi T; Nakanishi Y
    J Chromatogr; 1988 Mar; 425(1):203-7. PubMed ID: 3360871
    [No Abstract]   [Full Text] [Related]  

  • 55. [Metabolites of cyclandelate. Vasodilator action and inhibition of phosphodiesterase by metabolites of cyclandelate].
    Himber J; De Burlet G; Andermann G
    Ann Pharm Fr; 1987; 45(3):233-41. PubMed ID: 3434974
    [No Abstract]   [Full Text] [Related]  

  • 56. [Clinical and electroencephalographic studies of the effect of nicergoline in cerebrovascular diseases].
    Montanini R; Gasco P; Manfredini G
    Acta Neurol (Napoli); 1973; 28(2):133-49. PubMed ID: 4575428
    [No Abstract]   [Full Text] [Related]  

  • 57. [Study of the bioavailability of drugs with a cyclandelate base].
    Andermann G; Dietz M; Mergel D
    Pharm Acta Helv; 1979; 54(12):366-9. PubMed ID: 583451
    [No Abstract]   [Full Text] [Related]  

  • 58. Letter: Cyclandelate and improved brain function.
    Wechsler AF
    Am J Psychiatry; 1974 Jun; 131(6):723. PubMed ID: 4827806
    [No Abstract]   [Full Text] [Related]  

  • 59. [Clinical aspects and treatment of chronic cerebral circulatory disorders].
    Ishchenko MM; Shkrobot SI
    Vrach Delo; 1979 May; (5):33-7. PubMed ID: 452588
    [No Abstract]   [Full Text] [Related]  

  • 60. Cyclandelate versus propranolol in the prophylaxis of migraine--a double-blind placebo-controlled study.
    Gerber WD; Schellenberg R; Thom M; Haufe C; Bölsche F; Wedekind W; Niederberger U; Soyka D
    Funct Neurol; 1995; 10(1):27-35. PubMed ID: 7649498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.